163 related articles for article (PubMed ID: 33392443)
1. Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials.
Sedhom R; Ferrell B; Ruel N; Koczywas M; Chung V; Smith TJ
JNCI Cancer Spectr; 2020 Dec; 4(6):pkaa067. PubMed ID: 33392443
[TBL] [Abstract][Full Text] [Related]
2. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
3. The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events.
Kawaguchi T; Azuma K; Sano M; Kim S; Kawahara Y; Sano Y; Shimodaira T; Ishibashi K; Miyaji T; Basch E; Yamaguchi T
J Patient Rep Outcomes; 2017; 2(1):2. PubMed ID: 29757309
[TBL] [Abstract][Full Text] [Related]
4. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
[TBL] [Abstract][Full Text] [Related]
5. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
6. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
[TBL] [Abstract][Full Text] [Related]
7. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.
Reeve BB; McFatrich M; Mack JW; Maurer SH; Jacobs SS; Freyer DR; Withycombe JS; Baker JN; Castellino SM; Lin L; Lucas NR; Hinds PS
J Natl Cancer Inst; 2020 Nov; 112(11):1143-1152. PubMed ID: 31999349
[TBL] [Abstract][Full Text] [Related]
8. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.
Yang SS; Chen L; Liu Y; Lu HJ; Huang BJ; Lin AH; Sun Y; Ma J; Xie FY; Mao YP
BMC Cancer; 2021 Jul; 21(1):860. PubMed ID: 34315423
[TBL] [Abstract][Full Text] [Related]
9. Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
Mazza GL; Petersen MM; Ginos B; Langlais BT; Heon N; Gounder MM; Mahoney MR; Zoroufy AJ; Schwartz GK; Rogak LJ; Thanarajasingam G; Basch E; Dueck AC
Qual Life Res; 2022 Apr; 31(4):1069-1080. PubMed ID: 34420143
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.
Dueck AC; Scher HI; Bennett AV; Mazza GL; Thanarajasingam G; Schwab G; Weitzman AL; Rogak LJ; Basch E
JAMA Oncol; 2020 Feb; 6(2):e193332. PubMed ID: 31556911
[TBL] [Abstract][Full Text] [Related]
11. A study demonstrating users' preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE
Jordan T; Nuamek T; Fornacon-Wood I; Califano R; Coote J; Harris M; Mistry H; Taylor P; Woolf D; Faivre-Finn C
Front Oncol; 2024; 14():1328871. PubMed ID: 38660130
[TBL] [Abstract][Full Text] [Related]
12. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
[TBL] [Abstract][Full Text] [Related]
13. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
15. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period.
Lee MK; Basch E; Mitchell SA; Minasian LM; Langlais BT; Thanarajasingam G; Ginos BF; Rogak LJ; Mendoza TR; Bennett AV; Schrag D; Mazza GL; Dueck AC
Qual Life Res; 2023 Jul; 32(7):2047-2058. PubMed ID: 36897529
[TBL] [Abstract][Full Text] [Related]
16. Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study.
Veldhuijzen E; Walraven I; Belderbos J
JMIR Cancer; 2021 Sep; 7(3):e26574. PubMed ID: 34519658
[TBL] [Abstract][Full Text] [Related]
17. A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy.
Christiansen MG; Pappot H; Jensen PT; Mirza MR; Jarden M; Piil K
J Patient Rep Outcomes; 2023 Jul; 7(1):72. PubMed ID: 37462855
[TBL] [Abstract][Full Text] [Related]
18. Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients.
Chung V; Sun V; Ruel N; Smith TJ; Ferrell BR
J Palliat Med; 2022 May; 25(5):720-727. PubMed ID: 34704841
[No Abstract] [Full Text] [Related]
19. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
20. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.
Sandler KA; Mitchell SA; Basch E; Raldow AC; Steinberg ML; Sharif J; Cook RR; Kupelian PA; McCloskey SA
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):44-52. PubMed ID: 30102201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
